Literature DB >> 18832840

A critical assessment of the current status of non-erosive reflux disease.

David Armstrong1.   

Abstract

Non-erosive reflux disease (NERD) has assumed increasing prominence in studies of gastroesophageal reflux disease (GERD), but it remains a challenge to define NERD precisely and to define its place in the investigation and treatment of GERD. Most simply, NERD may be defined as GERD in an individual who has no evidence of erosions at endoscopy. Unfortunately, the characteristic symptoms of GERD--heartburn and regurgitation--are insufficient to identify all GERD patients and, hence, the diagnosis of NERD is hampered by the lack of clear criteria for the symptomatic diagnosis of GERD. The diagnosis of NERD is hampered further by limited interobserver agreement on the endoscopic diagnosis of erosive esophagitis and by the fact that endoscopy is often performed soon after patients have discontinued therapy. Improvements in endoscopic technology will increase the likelihood of identifying small erosions or other reflux-related lesions; however, this will increase the proportion of patients considered to have erosive esophagitis without defining precisely what constitutes NERD. It is important to recognize that NERD is but one manifestation of GERD and that it, like other manifestations of GERD, is associated with a marked diminution in patients' quality of life. However, this recognition apart, there seems to be little practical benefit or understanding to be gained in clinical practice or clinical research from considering NERD as a distinct entity or from studying NERD patients in isolation. Advances in understanding the pathogenesis of GERD and its symptoms may be better served by categorizing GERD with respect to the spectrum of its histologic, functional, endoscopic and symptomatic manifestations rather than by studying NERD, a manifestation that is characterized solely by the absence of esophageal erosions. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18832840     DOI: 10.1159/000151255

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Symptom-histopathology relation in upper GI endoscopy.

Authors:  Emre Günay; Erkan Özkan; Hacı Mehmet Odabaşı; Hacı Hasan Abuoğlu; Cengiz Eriş; Mehmet Kamil Yıldız; Süleyman Atalay
Journal:  Ulus Cerrahi Derg       Date:  2013-09-01

2.  Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.

Authors:  Takayoshi Suzuki; Masashi Matsushima; Aya Masui; Shingo Tsuda; Jin Imai; Jun Nakamura; Yoko Tsukune; Tetsufumi Uchida; Hiroki Yuhara; Muneki Igarashi; Jun Koike; Tetsuya Mine
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

3.  Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.

Authors:  Victoria P Y Tan; Wai M Wong; Ting K Cheung; Kam C Lai; Ivan F N Hung; Pierre Chan; Roberta Pang; Benjamin C Y Wong
Journal:  J Gastroenterol       Date:  2011-05-03       Impact factor: 7.527

4.  Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.

Authors:  Xiao-Ping Niu; Bao-Ping Yu; Yun-Dong Wang; Zhen Han; Shao-Fen Liu; Chi-Yi He; Guo-Zheng Zhang; Wan-Chun Wu
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

5.  Gastroesophageal reflux disease after diagnostic endoscopy in the clinical setting.

Authors:  Nora B Zschau; Jane M Andrews; Richard H Holloway; Mark N Schoeman; Kylie Lange; William Ce Tam; Gerald J Holtmann
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

6.  Nonerosive gastroesophageal reflux disease and mild degree of esophagitis: comparison of symptoms endoscopic, manometric and pH-metric patterns.

Authors:  Michele Grande; Pierpaolo Sileri; Grazia Maria Attinà; Elisabetta De Luca; Paolo Ciano; Carolina Ilaria Ciangola; Federica Cadeddu
Journal:  World J Surg Oncol       Date:  2012-05-16       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.